Advertisement

Topics

J&J set back by negative panel vote for sirukumab

05:25 EDT 3 Aug 2017 | BioPharmaDive

Safety concerns led an advisory panel to recommend the FDA reject the IL-6 blocker.

Original Article: J&J set back by negative panel vote for sirukumab

NEXT ARTICLE

More From BioPortfolio on "J&J set back by negative panel vote for sirukumab"

Quick Search
Advertisement